| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/26/2004 | US20040167149 Aryl fused azapolycyclic compounds |
| 08/26/2004 | US20040167145 moderator of cholinergic agent; mixture of acetylcholinesterase inhibitors and opioiod receptor blockers |
| 08/26/2004 | US20040167142 Pyrimidinone compounds |
| 08/26/2004 | US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease |
| 08/26/2004 | US20040167138 Antiischemic agents; brain disorders |
| 08/26/2004 | US20040167137 Xanthine phosphodiesterase V inhibitors |
| 08/26/2004 | US20040167134 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/26/2004 | US20040167133 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/26/2004 | US20040167125 such as sertindole, quetiapine and ziprasidone; use of combination to treat schizophrenia; synergistic mixture gives a more more rapid decrease in schizophrenic symptomology improving patient compliance |
| 08/26/2004 | US20040167118 Novel diarylalkene derivatives and novel diarylalkane derivatives |
| 08/26/2004 | US20040167105 Osteoporosis; anticancer agents; autoimmune disease |
| 08/26/2004 | US20040167091 Methods for treating ocular neovascular diseases |
| 08/26/2004 | US20040167089 Immunostimulatory nucleic acid molecules |
| 08/26/2004 | US20040167081 Method for the prevention and treatment of cachexia and anorexia |
| 08/26/2004 | US20040167077 Prevent skin damage; therapy for skin disorders |
| 08/26/2004 | US20040167075 Diagnosis, therapy od Alzheimer's disease; blocking psychological conditions |
| 08/26/2004 | US20040167074 Therapeutic applications of mFLINT polypeptides |
| 08/26/2004 | US20040167065 human transferases and polynucleotides which identify and encode them; expression vectors, host cells, antibodies, agonists, and antagonists; diagnosing, treating, or preventing disorders associated with aberrant expression of the transferases |
| 08/26/2004 | US20040167060 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 08/26/2004 | US20040166565 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors |
| 08/26/2004 | US20040166559 Vectors for gene therapy |
| 08/26/2004 | US20040166543 Regulation of cell growth by MUC1 |
| 08/26/2004 | US20040166159 Brain diosrders; controlling dopamine concentration |
| 08/26/2004 | US20040166122 Adenovirus formulations |
| 08/26/2004 | US20040166090 Antitumor agents; induction apoptosis |
| 08/26/2004 | DE10303229A1 α-Liponsäure, Ambroxol und/oder Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen α-lipoic acid, ambroxol and / or inhibitors of the angiotensin converting enzyme (ACE) comprehensive drug preparation and their use for the treatment of neurodegenerative diseases |
| 08/26/2004 | CA2515658A1 Medicinal composition |
| 08/25/2004 | EP1449922A2 Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis |
| 08/25/2004 | EP1449921A2 Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides |
| 08/25/2004 | EP1449843A1 Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives |
| 08/25/2004 | EP1449834A2 Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| 08/25/2004 | EP1449542A1 Genetic remedies for neurodegenerative diseases |
| 08/25/2004 | EP1449541A1 Compositions inhibiting rejection in organ transplantation and method of using the same |
| 08/25/2004 | EP1449540A1 Cytokine-inducing material and cytokine-inducing instrument |
| 08/25/2004 | EP1449537A2 Methods for treating hypercoagulable states or acquired protein C deficiency |
| 08/25/2004 | EP1449534A1 Matrix metalloprotease inhibitor |
| 08/25/2004 | EP1449529A1 Protein Kinase C Inhibitors |
| 08/25/2004 | EP1449528A1 Treatment of respiratory diseases |
| 08/25/2004 | EP1449511A1 Use of Idebenone for the preservation of compositions |
| 08/25/2004 | EP1448986A2 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 08/25/2004 | EP1448794A2 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis |
| 08/25/2004 | EP1448771A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof |
| 08/25/2004 | EP1448770A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 08/25/2004 | EP1448602A2 Modified anti-tnf alpha antibody |
| 08/25/2004 | EP1448599A2 Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| 08/25/2004 | EP1448592A1 Steroidal compounds for inhibiting steroid sulphatase |
| 08/25/2004 | EP1448589A2 Sperm-specific cation channel, catsper2, and uses therefor |
| 08/25/2004 | EP1448588A2 Psma antibodies and protein multimers |
| 08/25/2004 | EP1448567A1 Method for the preparation of hexahydro-furo 2,3-b]furan-3-ol |
| 08/25/2004 | EP1448566A2 Chemokine receptor antagonists and methods of use thereof |
| 08/25/2004 | EP1448565A1 ADENOSINE A?2a? RECEPTOR ANTAGONISTS |
| 08/25/2004 | EP1448560A1 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS |
| 08/25/2004 | EP1448557A2 Heteroindanes: a new class of potent cannabimimetic ligands |
| 08/25/2004 | EP1448553A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 08/25/2004 | EP1448552A1 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23 |
| 08/25/2004 | EP1448550A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity |
| 08/25/2004 | EP1448548A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 08/25/2004 | EP1448546A1 Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
| 08/25/2004 | EP1448544A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 08/25/2004 | EP1448542A1 6-hydroxy isoflavones, derivatives and medicaments involving same |
| 08/25/2004 | EP1448539A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 08/25/2004 | EP1448536A1 Cyclopropyl-containing oxazolidinone antibiotics and derivatives thereof |
| 08/25/2004 | EP1448535A1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 08/25/2004 | EP1448534A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition ofthe coagulation cascade |
| 08/25/2004 | EP1448529A1 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies |
| 08/25/2004 | EP1448528A2 Preparation of pharmaceutical salts of 4((z)-(4-bromophenyl)(ethoxyimino)methyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-4'-methyl-1,4'bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
| 08/25/2004 | EP1448526A1 Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| 08/25/2004 | EP1448524A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 08/25/2004 | EP1448523A1 Heterocyclic compounds and methods of use |
| 08/25/2004 | EP1448520A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use |
| 08/25/2004 | EP1448516A1 Hydroxyethylene compounds with asp2 inhibitory activity |
| 08/25/2004 | EP1448513A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 08/25/2004 | EP1448504A2 Clusianon isomers and use thereof |
| 08/25/2004 | EP1448268A2 Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| 08/25/2004 | EP1448233A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic |
| 08/25/2004 | EP1448231A1 Topical delivery of codrugs |
| 08/25/2004 | EP1448223A2 Thymosin augmentation of genetic immunization |
| 08/25/2004 | EP1448222A1 Biphasic mixtures of glp-1 and insulin |
| 08/25/2004 | EP1448221A1 Injection solution comprising an lhrh antagonist |
| 08/25/2004 | EP1448215A2 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections |
| 08/25/2004 | EP1448210A2 REGULATION OF cGMP-SPECIFIC PHOSPHODIESTERASE 9A |
| 08/25/2004 | EP1448205A2 Combinations for the treatment of immunoinflammatory disorders |
| 08/25/2004 | EP1448204A1 New dry and aqueous epinastine-syrup-formulation |
| 08/25/2004 | EP1448202A1 Combination of a pde4 or pde3/4 inhibitor and an anti-rheumatic drug |
| 08/25/2004 | EP1448200A2 (4-phenyl)piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 08/25/2004 | EP1448199A1 Benzimidazoles useful as protein kinase inhibitors |
| 08/25/2004 | EP1448198A1 Nicotin-or isonicotin benzothiazole derivatives |
| 08/25/2004 | EP1448196A1 Benzothiazole derivatives as adenosine receptor ligands |
| 08/25/2004 | EP1448195A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 08/25/2004 | EP1448194A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| 08/25/2004 | EP1448192A2 Novel methods of treating local fungal and bacterial infections |
| 08/25/2004 | EP1448184A1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie s disease |
| 08/25/2004 | EP1448181A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 08/25/2004 | EP1448179A1 Substituted bicyclo 3.3.1 nonan-2,4,9-triones as pharmaceutical active ingredients |
| 08/25/2004 | EP1448176A2 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 08/25/2004 | EP1448171A2 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 08/25/2004 | EP1448167A1 New use of ethoxylated phytosterols and phytostanols |
| 08/25/2004 | EP1448155A1 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation |
| 08/25/2004 | EP1448150A2 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 08/25/2004 | EP1448127A1 Compositions for the treatment of infectious diseases |